{"id":"NCT00467870","sponsor":"Endo Pharmaceuticals","briefTitle":"Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men","officialTitle":"A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2007-05-01","resultsPosted":"2017-03-07","lastUpdate":"2017-10-05"},"enrollment":531,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism","Primary Hypogonadism","Secondary Hypogonadism"],"interventions":[{"type":"DRUG","name":"Testosterone Undecanoate 750 mg","otherNames":[]},{"type":"DRUG","name":"Testosterone Undecanoate 1000 mg","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"To evaluate the pharmacokinetics of TU 750 mg and TU 1000 mg via multiple measurements of serum total testosterone.","primaryOutcome":{"measure":"Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval in Part C","timeFrame":"Days 0, 4, 7, 11, 14, 21, 28, 42, 56, and 70 post injection at week 14","effectByArm":[{"arm":"C-TU 750 mg","deltaMin":94,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":13},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":272},"commonTop":["Sinusitis","Upper respiratory tract infection","Prostatic specific antigen increased","Nasopharyngitis","Prostatitis"]}}